MarketResearchNest.com adds “Liver Fibrosis – Pipeline Review, H2 2017” new report to its research database. The report spread across 216 pages with table and figures in it.
Liver Fibrosis – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis – Pipeline Review, H2 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape.
Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.
Browse full table of contents and data tables at
The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 7, 3, 1, 1, 51 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.
Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Allergan Plc, Angion Biomedica Corp, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Bristol-Myers Squibb Company, Cellmid Ltd,
ContraVir Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, FibroGen Inc, Galectin Therapeutics Inc,
Galmed Pharmaceuticals Ltd, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd,
Immuron Ltd, Intercept Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Mission Therapeutics Ltd, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262573
– The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RandD brief, MoA and other developmental activities.
– The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Liver Fibrosis on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain